24th October 2026, Saturday

TechPharus

Latest Posts

HealthTech News

  • Once-daily oral icotrokinra outperforms placebo in ulcerative colitis
    on October 24, 2026 at 2:00 am

    For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according to a study published in the Oct. 15 issue of the New England Journal of Medicine.

  • Diagnostic test could help doctors refine prostate cancer treatment
    on October 24, 2026 at 12:40 am

    Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life.

  • Reprogramming tumor microenvironment could improve prospects for treatment of pancreatic cancer
    on October 23, 2026 at 11:40 pm

    Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is the dense tissue surrounding the tumor that acts as a protective barrier and suppresses the immune response. It is a complex tissue made of supporting cells, blood vessels and immune cells—the tumor microenvironment. In pancreatic cancer, this surrounding tissue accounts for up to 90% of the tumor mass.

  • Tegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
    on October 23, 2026 at 10:30 pm

    The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function benefit at 18 months. A recent analysis of BESTOW data found that tegoprubart also caused greater improvements in patient-reported health-related quality of life compared with tacrolimus in study participants. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

  • US–Mexico border counties face high kidney disease–related mortality and low nephrologist availability
    on October 23, 2026 at 10:30 pm

    New research indicates that U.S.–Mexico border counties experience disproportionately elevated rates of death from chronic kidney disease (CKD), alongside reduced availability of nephrologists. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.